Evidence and Research
Today's PrEP research agenda seeks to clarify how to deliver what's available—and identify new strategies.
PrEP research today spans implementation research on delivering daily oral tenofovir-based PrEP and clinical trials of new agents, including vaginal ARV-containing rings and long-acting injectables. Policy and program decisions are guided by data from the original randomized clinical trials as well as newer studies. There are many moving pieces and many product types.
No single PrEP option—and no single prevention option—is right for all people, or for any one person all the time. Demonstration projects are providing information about what's available, even as research continues for additional options.
Read below to find out more about evidence from: